U.S. Markets open in 5 hrs 3 mins
  • S&P Futures

    3,594.75
    -6.75 (-0.19%)
     
  • Dow Futures

    28,827.00
    +26.00 (+0.09%)
     
  • Nasdaq Futures

    10,962.50
    -73.00 (-0.66%)
     
  • Russell 2000 Futures

    1,673.00
    +3.20 (+0.19%)
     
  • Crude Oil

    83.16
    +3.67 (+4.62%)
     
  • Gold

    1,670.50
    -1.50 (-0.09%)
     
  • Silver

    19.34
    +0.30 (+1.58%)
     
  • EUR/USD

    0.9819
    +0.0018 (+0.1866%)
     
  • 10-Yr Bond

    3.8040
    0.0000 (0.00%)
     
  • Vix

    33.00
    +1.16 (+3.64%)
     
  • GBP/USD

    1.1208
    +0.0042 (+0.3743%)
     
  • USD/JPY

    145.0100
    +0.2810 (+0.1941%)
     
  • BTC-USD

    19,193.42
    -89.19 (-0.46%)
     
  • CMC Crypto 200

    435.86
    -7.57 (-1.71%)
     
  • FTSE 100

    6,812.75
    -81.06 (-1.18%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

RedHill Biopharma (NASDAQ:RDHL) investors are sitting on a loss of 89% if they invested five years ago

·3 min read

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see fellow investors lose their hard-earned money. Spare a thought for those who held RedHill Biopharma Ltd. (NASDAQ:RDHL) for five whole years - as the share price tanked 89%. And we doubt long term believers are the only worried holders, since the stock price has declined 87% over the last twelve months. We really feel for shareholders in this scenario. It's a good reminder of the importance of diversification, and it's worth keeping in mind there's more to life than money, anyway.

Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.

View our latest analysis for RedHill Biopharma

RedHill Biopharma isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last half decade, RedHill Biopharma saw its revenue increase by 69% per year. That's well above most other pre-profit companies. So it's not at all clear to us why the share price sunk 14% throughout that time. It could be that the stock was over-hyped before. We'd recommend carefully checking for indications of future growth - and balance sheet threats - before considering a purchase.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

We regret to report that RedHill Biopharma shareholders are down 87% for the year. Unfortunately, that's worse than the broader market decline of 12%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 14% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 5 warning signs for RedHill Biopharma (1 is a bit unpleasant) that you should be aware of.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here